An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-31
DOI
10.1007/s40264-020-00904-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
- (2016) Silvia Minozzi et al. Expert Opinion On Drug Safety
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
- (2016) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies
- (2016) Ari Polachek et al. ARTHRITIS CARE & RESEARCH
- Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review
- (2016) Rishi J. Desai et al. ARTHRITIS CARE & RESEARCH
- Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
- (2016) Frank I. Scott et al. JAMA Dermatology
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
- (2015) L Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy
- (2015) Huifeng Yun et al. ARTHRITIS CARE & RESEARCH
- Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study
- (2015) Jeffrey R. Curtis et al. ARTHRITIS RESEARCH & THERAPY
- Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
- (2014) Alexis Ogdie et al. ANNALS OF THE RHEUMATIC DISEASES
- Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims
- (2014) H. Kumamaru et al.
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
- (2014) Philip J. Mease et al. DRUGS
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study
- (2013) John W Baddley et al. ANNALS OF THE RHEUMATIC DISEASES
- Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
- (2013) V P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
- (2013) M. E. Weinblatt et al. JOURNAL OF RHEUMATOLOGY
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Mycobacterial diseases and antitumour necrosis factor therapy in USA
- (2012) KL Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases
- (2012) Kevin Haynes et al. ARTHRITIS AND RHEUMATISM
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
- (2012) Jeffrey R. Curtis et al. ARTHRITIS CARE & RESEARCH
- Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?
- (2011) B. P. Yawn et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients
- (2011) Jeffrey R. Curtis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases
- (2011) A. Bharat et al. ARTHRITIS CARE & RESEARCH
- Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis
- (2010) M. S. KRATHEN et al. JOURNAL OF RHEUMATOLOGY
- The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy
- (2010) Kevin L. Winthrop et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Cardiovascular morbidity in psoriatic arthritis
- (2008) D D Gladman et al. ANNALS OF THE RHEUMATIC DISEASES
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients
- (2008) Nivedita M. Patkar et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started